Compare Stocks: VRDN, KRYS, NUVL, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$58.95 -3.0%	$64.77	$41.71 ▼ $86.74	$9.80B	0.41	2.42 million shs	913,366 shs
KRYS Krystal Biotech	$336.40 -2.0%	$346.14	$136.73 ▼ $382.54	$9.96B	0.53	340,861 shs	75,273 shs
NUVL Nuvalent	$123.96	$123.76	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
VRDN Viridian Therapeutics	$24.16 -2.6%	$19.49	$13.18 ▼ $34.29	$2.74B	0.91	2.20 million shs	383,790 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	+1.98%	+7.55%	+14.83%	-19.77%	+43.13%
KRYS Krystal Biotech	+3.16%	+3.15%	+1.21%	+12.86%	+138.50%
NUVL Nuvalent	0.00%	0.00%	0.00%	+22.44%	+66.01%
VRDN Viridian Therapeutics	+3.64%	+8.39%	+33.62%	+40.19%	+39.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$58.95 -3.0%	$64.77	$41.71 ▼ $86.74	$9.80B	0.41	2.42 million shs	913,366 shs
KRYS Krystal Biotech	$336.40 -2.0%	$346.14	$136.73 ▼ $382.54	$9.96B	0.53	340,861 shs	75,273 shs
NUVL Nuvalent	$123.96	$123.76	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
VRDN Viridian Therapeutics	$24.16 -2.6%	$19.49	$13.18 ▼ $34.29	$2.74B	0.91	2.20 million shs	383,790 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	+1.98%	+7.55%	+14.83%	-19.77%	+43.13%
KRYS Krystal Biotech	+3.16%	+3.15%	+1.21%	+12.86%	+138.50%
NUVL Nuvalent	0.00%	0.00%	0.00%	+22.44%	+66.01%
VRDN Viridian Therapeutics	+3.64%	+8.39%	+33.62%	+40.19%	+39.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$94.15	54.85% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	6.43% Upside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
VRDN Viridian Therapeutics	2.86	Moderate Buy	$38.93	56.97% Upside

Current Analyst Ratings Breakdown

Latest VRDN, KRYS, NUVL, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Market Perform	$60.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/18/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/4/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$378.00 ➝ $386.00
8/3/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/3/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$72.00 ➝ $76.00
8/3/2026	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$944M	10.70	N/A	N/A	$2.65 per share	22.94
KRYS Krystal Biotech	$389.13M	26.12	$7.52 per share	45.66	$45.92 per share	7.48
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
VRDN Viridian Therapeutics	$70.85M	39.66	N/A	N/A	$4.98 per share	4.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.03	36.80	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	N/A
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest VRDN, KRYS, NUVL, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.08	-$0.69	+$0.39	-$0.69	$189.10 million	$267.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
KRYS Krystal Biotech	N/A	8.32	7.96
NUVL Nuvalent	N/A	16.14	16.14
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
KRYS Krystal Biotech	86.29%
NUVL Nuvalent	97.26%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	1.81%
KRYS Krystal Biotech	13.10%
NUVL Nuvalent	5.02%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

VRDN, KRYS, NUVL, and IONS Headlines

Recent News About These Companies

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20 at 4:55 AM | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19 at 5:20 AM | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18 at 6:31 AM | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18 at 5:52 AM | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18 at 3:12 AM | marketbeat.com

Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $38.93

August 16, 2026 | americanbankingnews.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Issues Negative Outlook for VRDN Earnings

August 10, 2026 | americanbankingnews.com

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

August 10, 2026 | marketbeat.com

Truist Financial Boosts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $39.00

August 9, 2026 | americanbankingnews.com

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

August 8, 2026 | finance.yahoo.com

Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN

August 8, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

August 8, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 7, 2026 | marketbeat.com

Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

August 7, 2026 | marketbeat.com

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

August 6, 2026 | businesswire.com

First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN

August 3, 2026 | marketbeat.com

Viridian Therapeutics, Inc. $VRDN Shares Sold by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Rating Lowered by Wall Street Zen

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, KRYS, NUVL, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$58.95 -1.85 (-3.04%)

As of 02:21 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Krystal Biotech NASDAQ:KRYS

$336.40 -6.94 (-2.02%)

As of 02:21 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nuvalent NASDAQ:NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Viridian Therapeutics NASDAQ:VRDN

$24.16 -0.64 (-2.58%)

As of 02:21 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, KRYS, NUVL, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, KRYS, NUVL, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, KRYS, NUVL, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, KRYS, NUVL, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Krystal Biotech NASDAQ:KRYS

Nuvalent NASDAQ:NUVL

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, KRYS, NUVL, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, KRYS, NUVL, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, KRYS, NUVL, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, KRYS, NUVL, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Krystal Biotech NASDAQ:KRYS

Nuvalent NASDAQ:NUVL

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools